Share on

Global HIV Diagnostics Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Product, Type, End User & Region - Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 2043
Pages: 180
Formats: report pdf report excel report power bi report ppt

HIV Diagnostics Market Size (2022 to 2027)

The global HIV diagnostics market size was valued at USD 2.86 Billion in 2022. It is further predicted to be growing at a CAGR of 9.5% and value USD 4.50 Billion by 2027.

The human immunodeficiency virus (HIV) infection refers to a retrovirus that causes AIDS. HIV affects immune cells, and it further weakens the immune system bringing loss of capacity to fight against the organisms that cause diseases. 


Y-O-Y growth in the population diagnosed with HIV and the rise in demand for technologically advanced devices for diagnosing HIV with high accuracy are majorly promoting the global HIV diagnostics market growth.

Other significant factors such as the growing adoption rate of home kits for diagnosis and testing of HIV, growing investments from private and government organizations for developing effective diagnostic techniques for treating HIV patients, and the emergence of simple, rapid assays with visual testing better handling are further accelerating the growth rate of the global HIV diagnostics market.

According to WHO, people diagnosing with HIV reaching millions, out of which a few million people die every year. AIDS is the advanced stage of HIV that affects the immune system. People whose CD4 cells are lower than 200/mm are diagnosing as AIDS patients. This HIV test uses blood, serum, or urine samples, where blood samples give accurate diagnosis results.

However, governments worldwide have conducted campaigns, educational seminars in colleges, corporate places, and other public places to bring awareness to people. Recently Kenya Medical Research Institute has introduced its new Cobas Plasma Separation Card to collect samples and test them quickly. 


The inappropriate functioning of regulatory bodies with stringent rules is one of the significant restraints to market growth. Additionally, High costs associated with Nucleic acid testing (NAT) and advanced diagnostics of HIV, and lack of a proper regulatory framework for NAT in developing countries are further expected to hamper the growth rate of the global HIV diagnostics market.

Impact of COVID-19 on the global HIV diagnostics market:

The emergence of global pandemic COVID-19 had negatively impacted the HIV diagnostics market. The HIV Diagnostic market had experienced a decline in market growth during the initial period of 2020.  The nationwide lockdown is imposed to disrupt the transmission of the disease. COVID-19 pandemic, it limited the movement of the people and access to quality healthcare. A movement in the healthcare system's focus impacted all healthcare programs worldwide. All resources were diverted to the COVID-19 pandemic, causing existing activities for communicable and non-communicable illnesses to be disrupted. As a result, services such as promotion, prevention, treatment, and cure were impacted globally. HIV/AIDS was no exception, and it suffered as a result of the pandemic's effects.

According to a modelling exercise undertaken by the WHO and UNAIDS for Sub-Saharan Africa, a disruption in ART supply and preventive programs might increase HIV-related fatalities and new infections across the area. Countries were requested to develop their strategy to maintain HIV prevention and treatment services during the COVID-19 pandemic as a preventive step. The advances that the nations had made would be wiped away unless prompt action was taken to assure a continuing supply of medications and access to preventative services. However, the HIV Diagnostics market resulted in better growth due to national HIV programs supported by Civil society and international development partners.




Market Size Available

2021 to 2027

Base Year


Forecast Period

2022 to 2027

Segments Covered

By Product, Test Type, End-User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa


This market research report on the global HIV diagnostics market has been segmented and sub-segmented based on the product type, test type, end-user, and region.

HIV Diagnostics Market - By Product:

  • Consumables
    • Assays
    • Kits & Reagents
    • Others
  • Instruments
  • Software
  • Services

Based on the product, the consumables segment is estimated to play a dominating role among all in the global HIV diagnostics market during the forecast period. Factors such as the increasing incidence of HIV and AIDS, increased number of hospitals and laboratories and governments of various countries have started working aggressively to control HIV/AIDS are expected to favour the growth of the segment. 

HIV Diagnostics Market - By Test Type:

  • Antibody Tests
    • HIV Screening Tests
      • Elisa
      • Rapid Tests
      • Home Access Dried Blood Spots
    • HIV-1 Antibody Confirmatory Tests
      • Western Blot Tests
      • Indirect Immunofluorescence Assays (IFA)
      • Line Immunoassays
      • Radio-Immunoprecipitation Assays
    • HIV-2 & Group O Diagnostic Tests
      • Blood Antibody Tests
      • DBS Tests
      • Line ImmunoAssay (HIV2)
  • Viral Identification Tests
    • p24 Antigen Test
    • Qualitative PCR Tests
    • Viral Culture
  • CD4 Testing
  • Viral load testing
  • Early Infant Diagnostics

Based on type, the antibody tests segment is expected to be the leader in the global HIV diagnostics market during the forecast period due to the increasing account of blood donations, raising awareness of HIV and Aids among people, the emergence of novel and innovative medical practices and technological advancements.  

HIV Diagnostics Market - By End-User:

  • Diagnostic Laboratories
  • Hospitals
  • Blood Banks
  • Home Care Settings
  • Other End-Users

Based on end-user, the diagnostic laboratories segment is most lucrative segment in the global HIV Diagnostics market due to factors such as spreading awareness about HIV and AIDS among people in developing countries. Further, the increasing focus of private and government organizations to incline investments in developing advanced diagnostic laboratories with technologically advanced equipment and diagnostic techniques.

HIV Diagnostics Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Geographically, the global HIV diagnostics market was dominated by North America and accounted for a market share of 38% in the global market in 2020. Y-O-Y growth in the incidence of HIV, growing focus of key market participants on developing novel drugs are some of the significant factors propelling the North American market growth. Increasing awareness among people, government initiatives to prevent HIV, widening research, and development of health facilities are further boosting the growth rate of the North American market.

The Asia Pacific is next big regional market globally and growing at a significant rate due to high unmet demand in India and China. In APAC market, India and China are contributing heavily to the growth of this regional market.

The European market is predicted to showcase a promising CAGR between 2020 to 2025. Increase in disposable income and recently developed healthcare equipment to propel the demand of the market.

The Middle East and Africa region have a slow growth due to a lack of knowledge. In this region, South Africa has the highest HIV prevalence.


Notable participants leading the global HIV diagnostics market profiled in this report are Abbott Healthcare, Alere Inc, Bristol-Myers Squibb, Abbvie Inc, Gilead Sciences, Janssen Therapeutics, Merck & Co., Inc, BD Biosciences, VIIV Healthcare, Beckman Coulter, Partec, Sysmex, Apogee Flow Systems, Zyomyx Inc. and Mylan Inc.


  • The scientist team of Abbott laboratories has discovered a new subtype of HIV called HIV-1 Group M, subtype L., the Abbott laboratories team has announced the event of this new strain discovery in November 2019.   
  • Roche Company has announced that it is committed to expanding its Global Access program in developing and low economy countries to provide accessibility of cost-effective resources, to eliminate diseases in these regions where the prevalence of diseases is on a higher note.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample